A First-in-Human Trial of Safety and Efficacy of GEN1078 in Participants With Solid Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

3 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-01-29

Study Completion Date

2025-06-11

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this trial is to measure the following in participants with solid cancers who receive GEN1078.

* The side effects seen with GEN1078
* What the body does with GEN1078 once it is administered
* What GEN1078 does to the body once it is administered
* How well GEN1078 works against advanced solid tumors

Trial details include:

* The estimated trial duration is 8 months for an individual participant (the trial duration may vary for each participant).
* The treatment duration will be an estimated 3-month treatment period (the duration of treatment may vary for each participant).
* The visit frequency will be daily or visits every few days for the first few months.

All participants will receive active drug; no one will be given placebo.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid Tumors

NCT06573294

Advanced Malignant Solid Tumors Metastatic Malignant Solid Tumors

RECRUITING PHASE1

Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Solid Tumors as Monotherapy and as Combination Therapy

NCT06391775

Malignant Solid Tumor

TERMINATED PHASE1/PHASE2

Study of Safety and Antitumor Activity of GEN1056 in Participants With Advanced Solid Tumors

NCT05586321

Solid Tumor, Adult

COMPLETED PHASE1

GEN1046 Safety Trial in Patients With Malignant Solid Tumors

NCT03917381

Solid Tumors Non-small Cell Lung Cancer Urothelial Carcinoma +4 more

ACTIVE_NOT_RECRUITING PHASE1/PHASE2

GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors

NCT03576131

Colorectal Cancer Non-small Cell Lung Cancer Triple Negative Breast Cancer +4 more

TERMINATED PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Malignant Solid Tumor

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

No randomization will be performed in the Dose-escalation part. In Dose-expansion part, if two expansion doses are identified, participants will be randomized to either Expansion Dose 1 or Expansion Dose 2.

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Dose-Escalation

GEN1078 will be administered as monotherapy until one of the treatment discontinuation criteria has been met.

Group Type EXPERIMENTAL

GEN1078

Intervention Type DRUG

Specified dose on specified days.

Dose Expansion

GEN1078 will be administered as monotherapy until one of the treatment discontinuation criteria has been met.

Group Type EXPERIMENTAL

GEN1078

Intervention Type DRUG

Specified dose on specified days.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

GEN1078

Specified dose on specified days.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Must have at least 1 measurable lesion per RECIST v1.1 assessed by the investigator.
* Must have an Eastern Cooperative Oncology Group performance status (ECOG PS) score of 0 to 1.

Dose Escalation Only

* Participant must have histologically or cytologically confirmed solid tumor(s) for which there is no further available standard therapy likely to confer clinical benefit (or participant is not a candidate or has previously refused such earlier available therapy), and for whom, in the opinion of the investigator, experimental therapy with GEN1078 may be beneficial.
* Must have either recurrence after, or progression on available relevant standard of care (SoC) anticancer therapies; or are deemed intolerant to or ineligible for, standard curative therapy in the recurrent setting.

Expansion Only

* Participant must have advanced (unresectable) or metastatic, histologically confirmed diagnosis of selected solid cancers.

Exclusion Criteria

* Has significant cardiovascular impairment within 6 months prior to the first dose of trial drug, including presence of unstable angina, myocardial infarction, congestive heart failure (New York Heart Association \[NYHA\] class III and IV), or clinically significant cardiac arrhythmia (other than stable atrial fibrillation) requiring anti-arrhythmia therapy.
* Known unstable central nervous system (CNS) metastases or any active or history of carcinomatous meningitis.
* Has been exposed to any of the following prior therapies within the specified timeframes:

* Prior therapy with a compound targeting the same targets as GEN1078 or any cell-based therapies.
* Radiotherapy within 14 days prior to C1D1. Palliative radiotherapy of bone metastases up to 7 days prior to C1D1 will be allowed.
* Treatment with any investigational or non-investigational anticancer agent (including investigational vaccines) or used an invasive investigational medical device within 28 days or 5 half-lives of the drug, whichever is shorter, prior to the first dose of GEN1078.
* Chemotherapy within 2 weeks prior to the first dose of GEN1078.
* Prophylaxis with live, attenuated vaccines within 28 days prior to first dose of GEN1078; or prophylaxis with the first and/or subsequent injection(s) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleic acid vaccine within 14 days prior to first dose of GEN1078.
* Chronic systemic immunosuppressive treatment, including corticosteroids, ie, prednisone \&gt;10 milligrams (mg) daily (or equivalent) or a cumulative dose \&gt;140 mg prednisone within 14 days (or equivalent) before the first dose of GEN1078. Replacement therapy (eg, physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is permitted.
* Has received granulocyte colony-stimulating factor (G-CSF) or granulocyte/macrophage colony stimulating factor support within 2 weeks prior to the first dose GEN1078 or being chronically transfusion dependent.
* Has received other T-cell activating surface marker. Note: Prior treatment with anti-T-cell Ig and ITIM domain (aTIGIT), anti-programmed cell death protein 1 (aPD1), anti-programmed death-ligand 1 (aPDL1), anti-lymphocyte activation gene 3 protein (aLAG3), anti-cytotoxic T-lymphocyte-associated protein 4 (aCTLA-4) is allowed.
* The initiation of growth factors and bisphosphonates is not allowed during the first 4 weeks of GEN1078 administration, unless agreed upon by the investigator and sponsor medical monitor. However, the use of receptor activator of nuclear factor kappa-Β ligand (RANK-L) inhibitors and bisphosphonates (if on stable dose for at least 4 weeks) is permitted while participating in this trial.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No